9 news items
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
will continue to be solely responsible for all clinical development of olverembatinib prior to potential exercise of the option to license. Olverembatinib
Halozyme's ENHANZE Product Gets New Patent Grant in EU
ABBV
ABOS
ALXO
6 Jun 24
on Jun 5 in response to the encouraging news. Year to date, the stock has jumped 23.5% against the industry's 5.6% decline
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
."
Takeda will be responsible for submission of potential regulatory filings based on the HD21 study outside of the U.S
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
ACIU
TAK
13 May 24
-Abeta active immunotherapy candidate designed to induce an antibody response against the toxic forms of Abeta believed to drive plaque formation
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
for the treatment of Alzheimer's disease. ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against
uv869aasv006bx47qosg5wcxl7nn5
ACIU
TAK
13 May 24
response against the toxic forms of Abeta believed to drive plaque formation and Alzheimer's disease progression. By inducing plaque clearance
grbxpdfbpv i6dknnc
TAK
22 Apr 24
. In response to this challenge, the three companies have been engaged in discussions to establish a joint venture company that will seamlessly cover the entire
1okw7hvku9nru1gb9ay6xubv84nd8xwyv0rpfhp26mqlbjoc
TAK
18 Apr 24
formulation of ENTYVIO as maintenance therapy in adult patients with moderately to severely active CD who had clinical response** at Week 6
m0ckkd8e5gi2g4ok5z2x6o xhnrhjt1
TAK
19 Mar 24
that reflects deep molecular and clinical responses and is an important prognostic indicator for long-term outcomes for patients with Ph+ ALL. ICLUSIG
- Prev
- 1
- Next